(Q45121026)

9 December 2017

title

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial (English)

1 reference

9 December 2017

1 reference

1 reference

24

Jeffrey M Drazen

0 references

Stanley J Szefler

21

object named as

Stanley J Szefler

1 reference

9 December 2017

14

Robert F Lemanske

1 reference

9 December 2017

9

John V Fahy

1 reference

9 December 2017

20

Christine A Sorkness

1 reference

9 December 2017

4

Homer A Boushey

1 reference

9 December 2017

2

Vernon M Chinchilli

1 reference

9 December 2017

11

Monica Kraft

1 reference

9 December 2017

7

Aaron Deykin

1 reference

9 December 2017

22

Michael E Wechsler

1 reference

9 December 2017

12

Susan J Kunselman

1 reference

National Heart, Lung, and Blood Institute's Asthma Clinical Research Network

9 December 2017

25

object named as

National Heart, Lung, and Blood Institute's Asthma Clinical Research Network

1 reference

9 December 2017

8

Joanne K Fagan

1 reference

9 December 2017

Elliot Israel

1

1 reference

9 December 2017

Jean G Ford

3

1 reference

9 December 2017

Reuben Cherniack

5

1 reference

9 December 2017

Timothy J Craig

6

1 reference

9 December 2017

James Fish

10

1 reference

9 December 2017

Stephen C Lazarus

13

1 reference

9 December 2017

Stephen B Liggett

15

1 reference

9 December 2017

Richard J Martin

16

1 reference

9 December 2017

Nandita Mitra

17

1 reference

9 December 2017

Stephen P Peters

18

1 reference

9 December 2017

Eric Silverman

19

1 reference

9 December 2017

Scott T Weiss

23

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

1 reference

9 December 2017

volume

364

1 reference

9 December 2017

issue

9444

1 reference

9 December 2017

page(s)

1505-1512

1 reference

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Asthma control during and after cessation of regular beta 2-agonist treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Quality control within the Asthma Clinical Research Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

High level multiplex genotyping by MALDI-TOF mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

Beta-agonists and asthma: too much of a good thing?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917273-5

7 January 2021

10.1016/S0140-6736(04)17273-5

Identifiers

DOI

1 reference

9 December 2017

1 reference